HK1203407A1 - Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof [12-b] - Google Patents
Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof [12-b]Info
- Publication number
- HK1203407A1 HK1203407A1 HK15104152.9A HK15104152A HK1203407A1 HK 1203407 A1 HK1203407 A1 HK 1203407A1 HK 15104152 A HK15104152 A HK 15104152A HK 1203407 A1 HK1203407 A1 HK 1203407A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- imidazo
- pyridazine
- compositions
- based compounds
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261608758P | 2012-03-09 | 2012-03-09 | |
| PCT/US2013/029043 WO2013134219A1 (en) | 2012-03-09 | 2013-03-05 | Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1203407A1 true HK1203407A1 (en) | 2015-10-30 |
Family
ID=48014284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15104152.9A HK1203407A1 (en) | 2012-03-09 | 2015-04-29 | Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof [12-b] |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US8969565B2 (es) |
| EP (1) | EP2822559B1 (es) |
| JP (1) | JP6418949B2 (es) |
| KR (1) | KR102085121B1 (es) |
| CN (1) | CN104470523B (es) |
| AR (1) | AR090291A1 (es) |
| AU (1) | AU2013230119B2 (es) |
| BR (1) | BR112014022271B1 (es) |
| CA (1) | CA2866164C (es) |
| ES (1) | ES2676826T3 (es) |
| HK (1) | HK1203407A1 (es) |
| IL (1) | IL234485A (es) |
| MX (1) | MX347917B (es) |
| NZ (1) | NZ630719A (es) |
| RU (1) | RU2014140739A (es) |
| SG (1) | SG11201405563VA (es) |
| TW (1) | TW201341385A (es) |
| UY (1) | UY34669A (es) |
| WO (1) | WO2013134219A1 (es) |
| ZA (1) | ZA201406148B (es) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2210891A1 (en) * | 2009-01-26 | 2010-07-28 | Domain Therapeutics | New adenosine receptor ligands and uses thereof |
| ES2834093T3 (es) | 2011-07-21 | 2021-06-16 | Sumitomo Dainippon Pharma Oncology Inc | Inhibidores de proteína quinasa heterocíclicos |
| PT2834243T (pt) | 2012-03-09 | 2018-08-01 | Lexicon Pharmaceuticals Inc | Compostos à base de pirazolo[1,5-a]pirimidina, composições que os compreendem e métodos para a sua utilização |
| US8901305B2 (en) | 2012-07-31 | 2014-12-02 | Bristol-Myers Squibb Company | Aryl lactam kinase inhibitors |
| JP2016509066A (ja) | 2013-02-22 | 2016-03-24 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | アダプター関連キナーゼ１（ａａｋ１）の阻害剤としての５ｈ−クロメノ［３，４−ｃ］ピリジン |
| AR097543A1 (es) * | 2013-09-06 | 2016-03-23 | Lexicon Pharmaceuticals Inc | COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO |
| JP6473146B2 (ja) | 2013-10-11 | 2019-02-20 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ピロロトリアジンキナーゼ阻害剤 |
| US10273237B2 (en) * | 2013-12-10 | 2019-04-30 | Bristol-Myers Squibb Company | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN-α responses |
| EA031863B1 (ru) * | 2014-01-24 | 2019-03-29 | ТиПи ТЕРАПЬЮТИКС, ИНК. | Диарильные макроциклы в качестве модуляторов протеинкиназ |
| MX2016009352A (es) * | 2014-01-31 | 2016-10-13 | Bristol Myers Squibb Co | Inhibidores de quinasa a base de quinolina. |
| TW201620911A (zh) * | 2014-03-17 | 2016-06-16 | 雷西肯製藥股份有限公司 | 銜接子關聯激酶１之抑制劑、包含其之組成物、及其使用方法 |
| EP3200797A1 (en) * | 2014-09-30 | 2017-08-09 | Bristol-Myers Squibb Company | Quinazoline-based kinase inhibitors |
| AU2015342887B2 (en) | 2014-11-06 | 2020-09-10 | Bial - R&D Investments, S.A. | Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders |
| US20170333435A1 (en) | 2014-11-06 | 2017-11-23 | Lysosomal Therapeutics Inc. | Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders |
| AU2015342883B2 (en) | 2014-11-06 | 2020-07-02 | Bial - R&D Investments, S.A. | Substituted pyrrolo(1,2-a)pyrimidines and their use in the treatment of medical disorders |
| US10174044B2 (en) | 2015-04-10 | 2019-01-08 | Bristol-Myers Squibb Company | Fused pyridines as kinase inhibitors |
| CN107735399B (zh) | 2015-07-02 | 2021-01-26 | 特普医药公司 | 作为蛋白质激酶的调节剂的手性二芳基大环 |
| CN113354653A (zh) * | 2015-07-06 | 2021-09-07 | 特普医药公司 | 二芳基大环多晶型物及其制备方法 |
| BR112018001065A2 (pt) * | 2015-07-21 | 2018-09-11 | Tp Therapeutics, Inc. | macrociclos diarila quirais e usos dos mesmos |
| KR20180081584A (ko) * | 2015-11-18 | 2018-07-16 | 브리스톨-마이어스 스큅 컴퍼니 | Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 이미다조피리다진 화합물 |
| MX2018012211A (es) | 2016-04-06 | 2019-03-28 | Lysosomal Therapeutics Inc | Compuestos de pirazol[1,5-a]pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos. |
| WO2017176961A1 (en) | 2016-04-06 | 2017-10-12 | Lysosomal Therapeutics Inc. | Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
| JP7034935B2 (ja) | 2016-04-06 | 2022-03-14 | リソソーマル・セラピューティクス・インコーポレイテッド | ピロロ［１，２－ａ］ピリミジニルカルボキサミド化合物および医学的障害の処置におけるその使用 |
| ES2957233T3 (es) * | 2016-04-15 | 2024-01-15 | Blueprint Medicines Corp | Inhibidores de quinasa tipo receptor de activina |
| EP3452455A4 (en) | 2016-05-05 | 2019-11-13 | Lysosomal Therapeutics Inc. | SUBSTITUTED IMDAZO [1,2-] PYRIDINES, SUBSTITUTED IMIDAZO [1,2-] PYRAZINES, RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF ILLNESSES |
| CN109311902B (zh) | 2016-05-05 | 2022-07-15 | Bial研发投资股份有限公司 | 取代的咪唑并[1,2-b]哒嗪、咪唑并[1,5-b]哒嗪、相关化合物及其用途 |
| TW201815799A (zh) | 2016-07-28 | 2018-05-01 | 美商Ｔｐ生物醫藥公司 | 巨環激酶抑制劑 |
| GB201617758D0 (en) | 2016-10-20 | 2016-12-07 | Almac Discovery Limited | Pharmaceutical compounds |
| TWI808958B (zh) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
| KR20180088113A (ko) * | 2017-01-26 | 2018-08-03 | 한미약품 주식회사 | 이미다조피리다진 화합물 |
| EP3597648B1 (en) * | 2017-03-14 | 2023-06-07 | Daiichi Sankyo Company, Limited | METHOD FOR PRODUCING 3, 6-DISUBSTITUTED IMIDAZO[1, 2-b]PYRIDAZINE DERIVATIVE |
| CN107082828B (zh) * | 2017-05-19 | 2019-09-17 | 暨南大学 | 一种活性氧响应性高分子载体及其制备方法 |
| KR102645316B1 (ko) | 2017-07-28 | 2024-03-07 | 터닝 포인트 테라퓨틱스, 인크. | 거대환형 화합물 및 이의 용도 |
| US10899733B2 (en) | 2017-08-23 | 2021-01-26 | Oregon Health & Science University | Inhibitors of PARPs that catalyze mono-ADP-ribosylation |
| JOP20200152A1 (ar) | 2017-12-19 | 2022-10-30 | Turning Point Therapeutics Inc | مركبات حلقية كبرى لعلاج مرض |
| CN113412262A (zh) | 2019-02-12 | 2021-09-17 | 大日本住友制药肿瘤公司 | 包含杂环蛋白激酶抑制剂的制剂 |
| CN110684028B (zh) * | 2019-10-28 | 2021-10-26 | 上海阿拉丁生化科技股份有限公司 | 一种2，6-二氮杂双环[3，3，0]辛烷类化合物的制备方法 |
| US20230159542A1 (en) * | 2020-04-21 | 2023-05-25 | The Uab Research Foundation | Rna-binding protein multimerization inhibitors and methods of use thereof |
| KR102590438B1 (ko) * | 2020-10-16 | 2023-10-18 | 김홍렬 | Pmca 억제제를 포함하는 코로나바이러스 감염 또는 감염 질환의 예방 또는 소독용 조성물 |
| KR102590444B1 (ko) * | 2020-10-16 | 2023-10-18 | 김홍렬 | Pmca 억제제를 포함하는 코로나바이러스 감염 또는 감염 질환의 치료용 조성물 |
| EP4291235A1 (en) * | 2021-02-12 | 2023-12-20 | Nimbus Saturn, Inc. | Hpk1 antagonists and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5464764A (en) | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
| WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| WO2007025090A2 (en) * | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase |
| US7750000B2 (en) * | 2005-09-02 | 2010-07-06 | Bayer Schering Pharma Ag | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments |
| US20070078136A1 (en) * | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| US20110021513A1 (en) | 2006-09-07 | 2011-01-27 | Biogen Idec Ma Inc. | Modulators of interleukin-1 receptor-associated kinase |
| CN101522682A (zh) | 2006-10-30 | 2009-09-02 | 诺瓦提斯公司 | 作为抗炎剂的杂环化合物 |
| FR2934994B1 (fr) * | 2008-08-12 | 2010-09-17 | Sanofi Aventis | Derives de 2-alkyl-6cycloamino-3-(pyridin-4-yl)imidaz°1,2-b! pyridazine, leur preparation et leur application en therapeutique |
| CA2738026C (en) * | 2008-09-22 | 2017-01-24 | Array Biopharma Inc. | Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors |
| WO2013134336A2 (en) | 2012-03-09 | 2013-09-12 | Lexicon Pharmaceuticals, Inc. | Inhibition of adaptor associated kinase 1 for the treatment of pain |
| PT2834243T (pt) | 2012-03-09 | 2018-08-01 | Lexicon Pharmaceuticals Inc | Compostos à base de pirazolo[1,5-a]pirimidina, composições que os compreendem e métodos para a sua utilização |
-
2013
- 2013-03-05 CA CA2866164A patent/CA2866164C/en active Active
- 2013-03-05 JP JP2014561020A patent/JP6418949B2/ja active Active
- 2013-03-05 KR KR1020147028073A patent/KR102085121B1/ko active IP Right Grant
- 2013-03-05 CN CN201380021272.3A patent/CN104470523B/zh active Active
- 2013-03-05 WO PCT/US2013/029043 patent/WO2013134219A1/en active Application Filing
- 2013-03-05 RU RU2014140739A patent/RU2014140739A/ru not_active Application Discontinuation
- 2013-03-05 SG SG11201405563VA patent/SG11201405563VA/en unknown
- 2013-03-05 ES ES13712953.2T patent/ES2676826T3/es active Active
- 2013-03-05 EP EP13712953.2A patent/EP2822559B1/en active Active
- 2013-03-05 BR BR112014022271-1A patent/BR112014022271B1/pt active IP Right Grant
- 2013-03-05 US US13/785,271 patent/US8969565B2/en active Active
- 2013-03-05 AU AU2013230119A patent/AU2013230119B2/en active Active
- 2013-03-05 NZ NZ630719A patent/NZ630719A/en unknown
- 2013-03-05 MX MX2014010584A patent/MX347917B/es active IP Right Grant
- 2013-03-08 TW TW102108279A patent/TW201341385A/zh unknown
- 2013-03-11 AR ARP130100764A patent/AR090291A1/es unknown
- 2013-03-11 UY UY0001034669A patent/UY34669A/es not_active Application Discontinuation
-
2014
- 2014-08-21 ZA ZA2014/06148A patent/ZA201406148B/en unknown
- 2014-09-07 IL IL234485A patent/IL234485A/en active IP Right Grant
-
2015
- 2015-02-25 US US14/631,097 patent/US20160024093A1/en not_active Abandoned
- 2015-04-29 HK HK15104152.9A patent/HK1203407A1/xx unknown
-
2016
- 2016-04-26 US US15/138,460 patent/US20170057964A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TW201341385A (zh) | 2013-10-16 |
| RU2014140739A (ru) | 2016-04-27 |
| KR20140138865A (ko) | 2014-12-04 |
| UY34669A (es) | 2013-10-31 |
| US20170057964A1 (en) | 2017-03-02 |
| MX2014010584A (es) | 2014-09-18 |
| BR112014022271A2 (es) | 2017-06-20 |
| EP2822559B1 (en) | 2018-05-02 |
| CN104470523B (zh) | 2017-07-11 |
| JP6418949B2 (ja) | 2018-11-07 |
| KR102085121B1 (ko) | 2020-03-05 |
| CA2866164C (en) | 2020-07-07 |
| US20130245021A1 (en) | 2013-09-19 |
| ZA201406148B (en) | 2016-06-29 |
| AU2013230119A1 (en) | 2014-09-25 |
| IL234485A (en) | 2017-02-28 |
| US8969565B2 (en) | 2015-03-03 |
| BR112014022271B1 (pt) | 2021-09-21 |
| MX347917B (es) | 2017-05-17 |
| US20160024093A1 (en) | 2016-01-28 |
| CN104470523A (zh) | 2015-03-25 |
| AU2013230119B2 (en) | 2017-02-23 |
| SG11201405563VA (en) | 2014-10-30 |
| CA2866164A1 (en) | 2013-09-12 |
| ES2676826T3 (es) | 2018-07-25 |
| JP2015509534A (ja) | 2015-03-30 |
| EP2822559A1 (en) | 2015-01-14 |
| NZ630719A (en) | 2017-01-27 |
| AR090291A1 (es) | 2014-11-05 |
| WO2013134219A1 (en) | 2013-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1203407A1 (en) | Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof [12-b] | |
| IL279304A (en) | History of cytotoxic benzodiazepines, preparations containing them and their uses | |
| HK1207374A1 (en) | Imidazo[1,2-b]pyridazine derivative as kinase inhibitor [12-b] | |
| HK1185881A1 (zh) | 取代的咪唑並 噠嗪 | |
| AP2014008084A0 (en) | Compositions comprising shortacting benzodiazepines | |
| EP2619203A4 (en) | TRICYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND APPLICATIONS THEREOF | |
| HK1217659A1 (zh) | 基於咪唑並 噠嗪的化合物、包含它們的組合物及其使用方法 | |
| PL2600719T3 (pl) | 2-Podstawione 8-alkilo-7-okso-7,8-dihydropirydo[2,3-d]pirymidyno-6-karbonitryle oraz ich zastosowania | |
| HK1197242A1 (en) | Fluoromethyl-5,6-dihydro-4h-[1,3]oxazines -56--4h-[13] | |
| ZA201404065B (en) | Tricyclic compounds, compositions comprising them and uses thereof | |
| EP2935280A4 (en) | 8'-HYDROXY-DIHYDROERGOTAMINE COMPOUNDS AND COMPOSITIONS | |
| IL233824A (en) | Compounds 1h - Indazole - 3 - Carboxamide, preparations containing them and their use | |
| IL280316B (en) | Amphiphilic compounds, preparations and their use | |
| IL237542B (en) | Amphiphilic compounds, their preparations and uses | |
| IL237540B (en) | Amphiphilic compounds, their preparations and uses | |
| IL237538A0 (en) | Amphiphilic compounds, their preparations and uses | |
| IL237539A0 (en) | Amphiphilic compounds, their preparations and uses | |
| IL232620A0 (en) | Tricyclic compounds, preparations including them and their use | |
| GB201223290D0 (en) | Don't lose it | |
| AU2012903933A0 (en) | Chaz's Knotchamacallit | |
| AU2012903507A0 (en) | Tee'd OFF | |
| AU2012903490A0 (en) | Tee'd OFF | |
| AU2012903488A0 (en) | Tee'd OFF | |
| AU2012903441A0 (en) | Tee'd OFF |